2-{2,3-dichloro-4-[(thiophen-2-yl)carbonyl]phenoxy}acetic acid
| Title | Journal |
|---|---|
| Cell-based assay using glutathione-depleted HepaRG and HepG2 human liver cells for predicting drug-induced liver injury. | Toxicology in vitro : an international journal published in association with BIBRA 20180401 |
| Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury. | Archives of toxicology 20180101 |
| Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. | Chemical research in toxicology 20170515 |
| High content analysis assay for prediction of human hepatotoxicity in HepaRG and HepG2 cells. | Toxicology in vitro : an international journal published in association with BIBRA 20160601 |
| Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions. | Journal of applied toxicology : JAT 20130201 |
| Identification of CYP isozymes involved in benzbromarone metabolism in human liver microsomes. | Biopharmaceutics & drug disposition 20121101 |
| Identification of protein targets of reactive metabolites of tienilic acid in human hepatocytes. | Chemical research in toxicology 20120521 |
| Differential oxidation of two thiophene-containing regioisomers to reactive metabolites by cytochrome P450 2C9. | Chemical research in toxicology 20120416 |
| Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator. | Drug metabolism and disposition: the biological fate of chemicals 20120401 |
| Idiosyncratic reactions and metabolism of sulfur-containing drugs. | Expert opinion on drug metabolism & toxicology 20120401 |
| Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. | BMJ (Clinical research ed.) 20120101 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. | Drug metabolism and disposition: the biological fate of chemicals 20110701 |
| CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. | Drug metabolism and disposition: the biological fate of chemicals 20110501 |
| A predictive ligand-based Bayesian model for human drug-induced liver injury. | Drug metabolism and disposition: the biological fate of chemicals 20101201 |
| Novel metabolic bioactivation mechanism for a series of anti-inflammatory agents (2,5-diaminothiophene derivatives) mediated by cytochrome p450 enzymes. | Drug metabolism and disposition: the biological fate of chemicals 20100901 |
| Characterization of glutathione conjugates of duloxetine by mass spectrometry and evaluation of in silico approaches to rationalize the site of conjugation for thiophene containing drugs. | Chemical research in toxicology 20100816 |
| Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase. | European journal of medicinal chemistry 20100201 |
| Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data. | BMC bioinformatics 20100101 |
| Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. | Drug metabolism and disposition: the biological fate of chemicals 20091201 |
| New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. | Current drug metabolism 20091201 |
| Aqua-(2,2'-bipyridine-κN,N')bis-(thio-phene-2-carboxyl-ato-κO)copper(II). | Acta crystallographica. Section E, Structure reports online 20090801 |
| Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development. | Xenobiotica; the fate of foreign compounds in biological systems 20090601 |
| Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection. | Drug metabolism and disposition: the biological fate of chemicals 20090101 |
| Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. | Current medicinal chemistry 20090101 |
| Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles. | PloS one 20090101 |
| Involvement of cytochrome P450-mediated metabolism in tienilic acid hepatotoxicity in rats. | Toxicology letters 20081215 |
| The crucial protective role of glutathione against tienilic acid hepatotoxicity in rats. | Toxicology and applied pharmacology 20081015 |
| Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. | Chemical research in toxicology 20080901 |
| Markers of electrophilic stress caused by chemically reactive metabolites in human hepatocytes. | Drug metabolism and disposition: the biological fate of chemicals 20080501 |
| A generic method to detect electrophilic intermediates using isotopic pattern triggered data-dependent high-resolution accurate mass spectrometry. | Rapid communications in mass spectrometry : RCM 20080401 |
| A novel approach to cyclin-dependent kinase 5/p25 inhibitors: A potential treatment for Alzheimer's disease. | Bioorganic & medicinal chemistry 20071001 |
| Changes in gene expression induced by tienilic Acid and sulfamethoxazole: testing the danger hypothesis. | Journal of immunotoxicology 20071001 |
| Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. | Critical reviews in toxicology 20070601 |
| Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. | Chemical research in toxicology 20070301 |
| Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: role of CYP2C isoforms in human liver microsomes. | Toxicology letters 20061215 |
| Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. | Drug metabolism and disposition: the biological fate of chemicals 20060801 |
| Tienilic acid enhances hyperbilirubinemia in Eisai hyperbilirubinuria rats through hepatic multidrug resistance-associated protein 3 and heme oxygenase-1 induction. | Toxicological sciences : an official journal of the Society of Toxicology 20060601 |
| Kinetics of tienilic acid bioactivation and functional generation of drug-protein adducts in intact rat hepatocytes. | Biochemical pharmacology 20051205 |
| Effects of novel ethacrynic acid derivatives on human trabecular meshwork cell shape, actin cytoskeletal organization, and transcellular fluid flow. | Biological & pharmaceutical bulletin 20051201 |
| Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. | Drug metabolism and disposition: the biological fate of chemicals 20051101 |
| Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. | Current drug metabolism 20051001 |
| Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. | Drug metabolism and disposition: the biological fate of chemicals 20050801 |
| Screening procedure for detection of diuretics and uricosurics and/or their metabolites in human urine using gas chromatography-mass spectrometry after extractive methylation. | Therapeutic drug monitoring 20050801 |
| Cytochrome P450 and liver diseases. | Current drug metabolism 20040601 |
| Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. | Archives of biochemistry and biophysics 20030101 |
| Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. | Archives of biochemistry and biophysics 20030101 |
| Immune-mediated drug-induced liver disease. | Clinics in liver disease 20020801 |
| Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. | Biochemistry 20011009 |
| Use of isotopes and LC-MS-ESI-TOF for mechanistic studies of tienilic acid metabolic activation. | Advances in experimental medicine and biology 20010101 |
| Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. | Chemical research in toxicology 19960101 |
| Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. | Hepatology (Baltimore, Md.) 19850101 |
| Vocal cord hematomas complicating anticoagulant therapy. | Annals of emergency medicine 19840701 |
| A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. | Clinical and experimental immunology 19840301 |
| Acute effects of alkylating agents on canine renal function and ultrastructure: high-dose ethacrynic acid vs. dihydroethacrynic acid and ticrynafen. | The Journal of pharmacology and experimental therapeutics 19840301 |
| Hepatotoxicity associated with ticrynafen--a uricosuric diuretic. | The American journal of gastroenterology 19820601 |
| Effects of prostaglandins inhibition on changes in active and inactive renin induced by antihypertensive drugs. | Clinical and experimental hypertension. Part A, Theory and practice 19820101 |
| Adverse reactions associated with ticrynafen use. | JAMA 19800201 |
| Tienilic acid in the treatment of mild to moderate hypertension. | Clinical and experimental pharmacology & physiology 19800101 |
| Comparison of natriuretic, uricosuric, and antihypertensive properties of tienilic acid, bendrofluazide, and spironolactone. | British medical journal 19790127 |